17 results
·
27ms
·
Sources: EU EUDAMED, US FDA
Pirouette High Pressure (HP)
FDA 510(k)
FDA Class 2
·Cardiovascular
External Fixation
FDA UDI
Life Spine, Inc.·00190837023102·Female Post, 1 Hole
Arena-C®
FDA UDI
SPINEFRONTIER, INC.·00190361036982·Trial Rasp, No Stop, Assembly, Straight, 6mm
Arena-C®
FDA UDI
SPINEFRONTIER, INC.·00190361037019·Trial Rasp, No Stop, Assembly, Straight, 9mm
Arena-C®
FDA UDI
SPINEFRONTIER, INC.·00190361037002·Trial Rasp, No Stop, Assembly, Straight, 8mm
Arena-C®
FDA UDI
SPINEFRONTIER, INC.·00190361037040·Trial Rasp, No Stop, Assembly, Straight, 12mm
Arena-C®
FDA UDI
SPINEFRONTIER, INC.·00190361037033·Trial Rasp, No Stop, Assembly, Straight, 11mm
Arena-C®
FDA UDI
SPINEFRONTIER, INC.·00190361037026·Trial Rasp, No Stop, Assembly, Straight, 10mm
Arena-C®
FDA UDI
SPINEFRONTIER, INC.·00190361036975·Trial Rasp, No Stop, Assembly, Straight, 5mm
Arena-C®
FDA UDI
SPINEFRONTIER, INC.·00190361036999·Trial Rasp, No Stop, Assembly, Straight, 7mm
COMBITRANS MONITORING SETS AND ACCESSORIES
FDA 510(k)
FDA Class 2
·Cardiovascular
OTODYNAMICS OTOPORT
FDA 510(k)
FDA Class 2
·Ear, Nose, Throat
ACCESS
FDA Adverse Event
Malfunction
·BAXTER HEALTHCARE - SINGAPORE·Product code FPA·June 17, 2013
SWAN-GANZ CCOMBO CCO/SVO2/VIP THERMODILUTION CATHETER WITH AMC THROMBOSHIELD
FDA Adverse Event
Malfunction
·EDWARDS LIFESCIENCES, PR·Product code DYG·July 22, 2011
LIFEPAK CR PLUS DEFIBRILLATOR
FDA Adverse Event
Malfunction
·PHYSIO-CONTROL, INC.·Product code MKJ·September 18, 2008
FIX PIN FLTD 3.2DX150MM 2 PACK
FDA Adverse Event
Injury
·ZIMMER CAS·Product code OLO·March 24, 2025
Merlin PCS Programmer software model 3330, used with Confirm Rx Insertable Cardiac Monitor (ICM), Model DM3500, Sterile. The firm name on the label of the ICM is St. Jude Medical Cardiac Rhythm Management Division, Sylmar, CA. - Product Usage: The Confirm Rx insertable cardiac monitor is designed to detect arrhythmias and wirelessly transmit data to the Merlin.net Patient Care Network. The Confirm Rx ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.
FDA Enforcement
Class II
·Terminated·St Jude Medical, Cardiac Rhythm Management Division·January 22, 2020